Acadia Pharma (ACAD) Tops Q4 EPS by 2c

Acadia Pharma (NASDAQ: ACAD) reported Q4 EPS of ($0.34), $0.02 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $98.3 million versus the consensus estimate of $96.76 million.

“In 2019 ACADIA demonstrated strong execution from our commercial and R&D teams, driving the continued growth of NUPLAZID and advancing our late-stage pipeline,” said Steve Davis, Chief Executive Officer. “2020 will be a transformational year for ACADIA highlighted by a potential approval in dementia-related psychosis, additional pivotal study results in major depressive disorder, commencement of a second pivotal study for the negative symptoms of schizophrenia and the continued enrollment of the Phase 3 trofinetide study for Rett syndrome. This exciting momentum has created a multi-year cadence of pivotal study readouts and potential regulatory approvals that position the company for long-term growth.”

GUIDANCE:

Acadia Pharma sees FY2020 revenue of $440-470 million.

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.

You May Also Be Interested In

• Kura Sushi (KRUS) Tops Q3 EPS by 3c; offers outlook
• Goldman Sachs Downgrades Banco Comercial Portugues (BCP:LI) (BPCGF) to Neutral
• Penguin Solutions (PENG) Tops Q2 EPS by 28c, Beats on Revenue; Offers FY26 EPS Guidance